Your session is about to expire
← Back to Search
ALLO-316 for Kidney Cancer (TRAVERSE Trial)
TRAVERSE Trial Summary
This trial is testing a new cancer treatment in people with advanced kidney cancer. The treatment will be given after a regimen to weaken the immune system. The goal is to find the safe dose for the treatment.
TRAVERSE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTRAVERSE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.TRAVERSE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not received anti-CD52 monoclonal antibody treatment in the last year.My kidney cancer is mainly made up of clear cells.I have a significant brain or nerve condition affecting my daily life.You have at least one specific type of tumor that can be measured according to certain guidelines.I have been treated with drugs targeting the immune system and blood vessel growth for my advanced cancer.I am fully active or restricted in physically strenuous activity but can do light work.My blood, kidney, liver, lung, and heart functions are all within normal ranges.My brain or spinal cord cancer has been stable for at least 4 weeks.I have previously been treated with anti-CD70 therapies.I have a thyroid disorder, but it's controlled hypothyroidism.I have not had any other cancer in the last 3 years.You don't have antibodies that can attack the donated product.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
What negative effects can result from the administration of ALLO-316?
"Our team at Power gave ALLO-316 a rating of 1, as this is merely a Phase 1 trial. Thus far there are just minimal evidence and studies to support the drug's safety and effectiveness."
Could I potentially qualify to participate in this experiment?
"This research initiative is open to 120 patients aged between 18 and 75 who are suffering from renal cell carcinoma. Furthermore, the individual must have a minimum of one visible lesion as outlined in RECIST version 1.1 and an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1."
Is the eligibility for this research restricted to those under 35?
"To be in compliance with the trial's criteria, participants must be 18 or older and not exceed 75 years of age."
Are there any precedential studies which have explored the potential of ALLO-316?
"Presently, 889 studies are underway for ALLO-316; of those active trials, 161 are in Phase 3. The epicentre is Philadelphia, PA but research sites span 28446 different locations around the globe."
Is this research project welcoming more participants?
"As indicated on clinicaltrials.gov, this research effort is currently open for enrollment and was initially posted in February 2021 with a recent edit in March 2022."
In what capacity is ALLO-316 typically employed?
"ALLO-316 is a popular drug used to treat multiple sclerosis, as well as mixed cell type lymphoma, leukemia, myelocytic acute and retinoblastoma."
In what geographic regions is this research endeavor being administered?
"Right now, there are 6 sites participating in this trial. These locations include Houston, Duarte and Portland as well as 3 other cities. To make the process more convenient for participants, it is recommended to enroll at the site nearest them."
How many individuals are currently participating in this experiment?
"In order for this trial to attain the necessary data, 120 qualified candidates need to volunteer. Those wishing to participate can do so at either MD Anderson Cancer Center in Houston or City of Hope in Duarte."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger